Literature DB >> 3289931

A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation.

R V Lewis1, E Laing, T A Moreland, E Service, D G McDevitt.   

Abstract

Fourteen patients (four females) with chronic atrial fibrillation were entered into a randomized, double-blind crossover study to compare the effects of treatment with diltiazem alone, digoxin alone, and a combination of diltiazem plus digoxin. The dose of digoxin was adjusted so as to achieve serum concentrations within the range 1.3-2.6 nmol l-1 between six and eight hours after dosing. Four patients were withdrawn from the study; three patients experienced side effects while taking diltiazem and one reverted to sinus rhythm while taking digoxin. Among the remaining 10 patients, mean heart rates were significantly lower during treatment with the combination of digoxin and diltiazem than with digoxin alone both at rest, after exercise and during ambulatory ECG monitoring. Post-exercise heart rates were reduced by 15% with combination therapy when compared with digoxin alone (151.9 vs. 128.1 bpm), but there was no evidence that this reduction in ventricular rate was associated with improved exercise tolerance. The results suggest that further reduction of the rapid ventricular rates seen in digitalized patients with AF by the use of diltiazem does not appear to be of benefit in the majority of patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3289931     DOI: 10.1093/oxfordjournals.eurheartj.a062497

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  11 in total

1.  Influence of physical exercise on serum digoxin concentration and heart rate in patients with atrial fibrillation.

Authors:  H E Bøtker; P Toft; N A Klitgaard; E E Simonsen
Journal:  Br Heart J       Date:  1991-06

Review 2.  Rate control in the medical management of atrial fibrillation.

Authors:  A J Camm; I Savelieva; G Y H Lip
Journal:  Heart       Date:  2006-09-04       Impact factor: 5.994

Review 3.  Atrial fibrillation. The therapeutic options.

Authors:  R V Lewis
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

4.  Rate control in permanent atrial fibrillation.

Authors:  Theodora Nikolaidou; Kevin S Channer
Journal:  BMJ       Date:  2007-11-24

Review 5.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

6.  Importance of rate control or rate regulation for improving exercise capacity and quality of life in patients with permanent atrial fibrillation and normal left ventricular function: a randomised controlled study.

Authors:  T Levy; S Walker; M Mason; P Spurrell; S Rex; S Brant; V Paul
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

7.  Magnesium deficiency may be an important determinant of ventricular ectopy in digitalised patients with chronic atrial fibrillation.

Authors:  R Lewis; C Durnin; J McLay; J McEwen; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

Review 8.  Atrial fibrillation: how to approach rate control.

Authors:  Lynda E Rosenfeld
Journal:  Curr Cardiol Rep       Date:  2005-09       Impact factor: 2.931

Review 9.  Diltiazem. A review of its pharmacology and therapeutic use in older patients.

Authors:  A Markham; R N Brogden
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

10.  Clinical pharmacology of chronic atrial fibrillation.

Authors:  R Lewis; J McClay
Journal:  J R Coll Physicians Lond       Date:  1988-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.